Pegloticase is an IV medicine used for adults with chronic gout when standard uric-acid-lowering treatments have not worked well enough or cannot be used. It acts like an enzyme that changes uric acid in the blood into allantoin, a substance the body can remove in urine. Lowering uric acid this way can help the body gradually clear gout deposits, but infusions require monitoring because serious reactions can occur.
Unlike many gout medicines that reduce uric acid production or help the kidneys remove it, pegloticase breaks down uric acid directly. This approach can be useful when gout continues to cause problems despite other treatments. Understanding how the medicine works, why it is reserved for certain adults, and what monitoring involves can help patients prepare for a discussion with their healthcare team.
How does pegloticase work in the body?
Gout develops when uric acid builds up and forms tiny crystals in and around joints. These crystals can trigger inflammation, causing episodes of pain, warmth, redness, and swelling. Over time, uric acid may also collect in firm deposits called tophi, which can develop under the skin or around joints.
Pegloticase, sold under the brand name Krystexxa in the United States, contains a specially prepared enzyme called uricase. The enzyme converts uric acid into allantoin, a substance that dissolves more readily in water and can be eliminated from the body, mainly through the kidneys. The U.S. National Library of Medicine's DailyMed prescribing information describes this conversion as the medicine's main mechanism of action.
When uric acid levels remain low enough, existing urate deposits can gradually shrink as the body clears them. Over time, this may reduce the burden of gout and help improve symptoms associated with persistent deposits. However, the rate of improvement varies, and lowering uric acid does not mean that joint symptoms will disappear immediately.
Who may benefit from pegloticase treatment?
Pegloticase is intended for adults with chronic gout that has not responded adequately to conventional treatment or who cannot use appropriate standard medicines. It is not generally the first treatment chosen for gout because many people can manage the condition with oral uric-acid-lowering medicines.
The American College of Rheumatology's guideline for gout management recommends considering a switch to pegloticase when other uric-acid-lowering approaches have failed and gout continues to cause frequent attacks or persistent tophi. The guideline recommends against switching to pegloticase when attacks are infrequent and tophi are absent, because the expected benefits may not outweigh the risks and costs.
A healthcare professional considers previous treatments, how well they lowered uric acid, ongoing gout symptoms, medication side effects, other medical conditions, and the patient's ability to attend regular infusions. A high uric acid result alone, without symptoms of gout, is not an indication for pegloticase under its U.S. prescribing information.
How is pegloticase given?
Pegloticase is administered through an intravenous infusion, meaning the medicine enters a vein through a needle or intravenous line. It is usually given once every two weeks in a healthcare setting. Each infusion takes at least two hours, and patients are observed afterward because reactions may occur during or following administration.
MedlinePlus explains that pegloticase is given by a doctor or nurse and that treatment may take several months to help prevent gout attacks. The healthcare team may provide medicines before the infusion to reduce the risk of an allergic reaction and prescribe preventive treatment for gout flares. Patients should attend scheduled appointments and follow their prescribed plan rather than adjusting treatment independently.
Why is methotrexate sometimes used with pegloticase?
In its current U.S. prescribing information, Krystexxa is recommended in combination with methotrexate and folic acid or folinic acid supplementation for eligible patients. Methotrexate is an immunomodulating medicine that can reduce the body's formation of antibodies against pegloticase. These antibodies may reduce the amount of active medicine in the body and contribute to treatment failure or a higher risk of infusion reactions.
The prescribing information describes a usual adult regimen of pegloticase every two weeks alongside weekly oral methotrexate and folate supplementation. Methotrexate and folate are generally started at least four weeks before pegloticase begins. Pegloticase alone may be considered when methotrexate is contraindicated or not clinically appropriate.
Methotrexate is not suitable for everyone and requires its own safety assessment and monitoring. The decision to use combination therapy depends on factors such as medical history, other medicines, laboratory results, and the risks associated with immunomodulating treatment. Patients should not start methotrexate or folic acid supplements specifically for gout without instructions from their prescribing clinician.
What happens during the first months of treatment?
Gout attacks may temporarily become more frequent after pegloticase begins. This can happen even when treatment is lowering uric acid effectively. Changes in uric acid levels can mobilize urate from deposits in tissues, and this process may trigger inflammation before the overall burden of crystals decreases.
To reduce this risk, clinicians commonly prescribe preventive treatment, such as colchicine or a nonsteroidal anti-inflammatory drug (NSAID), when appropriate. The treatment plan generally begins before the first infusion and continues during the early months of therapy. The exact choice and duration depend on the patient's other conditions, kidney function, medication tolerance, and risk of side effects.
A gout flare during treatment does not necessarily mean that pegloticase has failed. Patients should contact their healthcare team for advice about managing an attack and should not discontinue scheduled infusions on their own. The prescribing clinician can assess whether the symptoms represent a flare, another problem, or a change in treatment response.
How do doctors monitor whether pegloticase is working?
Monitoring is essential because pegloticase can lose effectiveness over time, particularly when the immune system develops antibodies against the medicine. Healthcare professionals measure blood uric acid before each infusion to check whether the medication is continuing to work as intended.
The current U.S. prescribing information recommends discontinuing pegloticase if serum uric acid rises above 6 mg/dL, particularly when levels are above that threshold on two consecutive checks. A rise may indicate loss of treatment response and an increased risk of serious infusion reactions. These results are used by the prescribing team to make treatment decisions; patients should not try to determine their response from an isolated laboratory value.
The healthcare team also reviews gout attacks, changes in tophi, joint symptoms, possible adverse effects, and the patient's overall response. The duration of treatment is individualized because the optimal total treatment duration has not been established. If pegloticase no longer provides adequate benefit or becomes unsafe, the clinician may recommend stopping it and discussing other options.
Oral uric-acid-lowering medicines, including allopurinol and febuxostat, are generally discontinued before pegloticase begins and are not usually started during treatment under the U.S. prescribing information. These medicines can mask a rise in uric acid that might otherwise alert the healthcare team to loss of response. The transition should be planned by the treating clinician; patients should not stop or restart their regular medicines without guidance.
What are the main risks and precautions?
Pegloticase can cause serious allergic reactions, including anaphylaxis, as well as other infusion reactions. These reactions may occur during an infusion or afterward, including with an early dose. Warning signs can include hives, itching, flushing, dizziness, chest discomfort, swelling of the face or throat, and difficulty breathing. Mayo Clinic's pegloticase drug information advises prompt medical attention for symptoms that may indicate a serious reaction.
For this reason, pegloticase is administered in a healthcare setting equipped to respond to severe infusion reactions. Patients typically receive preventive medicines before treatment and remain under observation afterward. Difficulty breathing, throat or tongue swelling, fainting, or other signs of a severe allergic reaction require immediate emergency medical attention.
Another important precaution concerns glucose-6-phosphate dehydrogenase (G6PD) deficiency, an inherited condition affecting red blood cells. Pegloticase can cause red blood cell breakdown and methemoglobinemia, a problem that reduces the blood's ability to carry oxygen, in people with this deficiency. The official U.S. prescribing information states that pegloticase must not be given to people with G6PD deficiency. Clinicians assess the need for testing before treatment, especially when inherited risk factors are present.
Other potential adverse effects include gout flares, joint pain, nausea, and fatigue. The medicine also requires caution in people with congestive heart failure because worsening heart failure has been reported. Patients should tell their healthcare team about heart problems, previous serious medication reactions, all prescription and nonprescription medicines, and any known G6PD deficiency before treatment begins.
What should patients discuss before starting pegloticase?
A useful appointment focuses on whether the expected benefits justify the treatment's risks and practical demands. Patients can discuss why other gout treatments have not achieved adequate control, whether methotrexate is appropriate, what tests are needed before the first infusion, and how flares will be prevented or treated.
It is also important to understand the infusion schedule, the need for regular blood tests, which symptoms require urgent attention, and what will happen if uric acid begins to rise again. Because pegloticase is not a treatment for an acute gout attack, a separate plan may be needed to manage pain and inflammation when a flare occurs.
Pegloticase offers a targeted option for some adults whose chronic gout remains difficult to control. Its distinctive enzyme action can lower uric acid substantially, but successful treatment depends on appropriate patient selection, preventive care, laboratory monitoring, and prompt recognition of adverse reactions.